PEPPI/PEPPI-PMOS
PMOS (Polyendocrine Metabolic Ovarian Syndrome, formerly PCOS) is the most common endocrine dysfunction in women, affecting 10–17 % of the fertile-aged female population. There is large-scale multimorbidity related to the syndrome, including adverse pregnancy outcomes.
The study is based on the PEPPI-trial that aimed to screen pre-eclampsia and adverse pregnancy outcomes in 3000 pregnancies in women living in the Oulu area. PEPPI study also included 2 other arms: PregPMOS (identifying women with PMOS by using AMH) and FERPPI (iron status during pregnancy).
We anticipated identifying a minimum of 300 women with PMOS, 300 women with risk for preeclampsia (PE), and 300 randomly selected controls with no PMOS and no risk for PE. All 3000 women were invited to provide a serum sample at the 3rd trimester (GW 30-32). The 900 selected women (PMOS, PE risk, control) were also invited for additional ultrasonography (GW 30-32). We accumulated data from the health records (ultrasonogpahy data 1st and 2nd trimester) and all visits to any health service providers during pregnancy. All data were finally linked to national health registers.
The offspring will be followed up to 17 years. Serum samples have been planned at this point at 3 months and 12 months of age. We can follow the children through national registers. 99% of children will visit health services for annual check-ups until the age of 15.
The study aimed at
1) Identifying pregnancy-related risks and outcomes in women with PMOS
2) Following the women with PMOS and non-PMOS controls up to delivery and looking for risk factors and outcomes in this population-based data set, including iron deficiency.
3) Following offspring born to “pregnancies at risk” up to the age of 17 years.
PEPPI-Research Team:
Principal Investigator in PEPPI, Associate Professor Jaana Nevalainen, MD
Principal Investigator in PEPPI-PMOS, Professor Terhi Piltonen, MD, PhD
